Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy

The main questions our trial aims to answer are:

• Can a centralized intervention designed to support and alert clinicians to the presence of LVH in their patients who are not being treated with blood pressure medications increase the diagnosis and treatment of hypertension?
• Can a centralized clinical support intervention aimed at thoroughly screening for hypertension in individuals with LVH lead to an increase in the diagnosis of other causes of thickened heart muscle such as infiltrative and genetic cardiomyopathies?

For subjects randomized to the intervention arm, centralized population health coordinators will notify the established longitudinal specialty provider (cardiologist or nephrologist) or the primary care physician (PCP) that their patient has a recent echocardiogram demonstrating LVH. The outpatient clinician will be notified via the electronic health record messaging system that the finding of LVH -- in the absence of significant valvular heart disease or a previously diagnosed cardiomyopathy -- may reflect undiagnosed or untreated hypertension. Through a structured correspondence with the identified clinician, the population health coordinator will offer to schedule a dedicated visit for the provider and their patient to discuss the finding of LVH. Additionally, the population health coordinator will offer to coordinate 24-hour ambulatory blood pressure monitoring before or after the patient visit as part of the evaluation of LVH. Finally, for subjects without established cardiovascular care and whose etiology of LVH remains undetermined, the population health coordinator will offer to coordinate a visit with a cardiologist to discuss the finding of LVH.

Researchers will compare subjects randomized to the intervention arm against those randomized to the observation arm to determine if there are: (1) higher rates of initiation of blood pressure medications, (2) increased diagnoses of hypertension, and (3) increased diagnoses of alternate causes of thickened heart muscle in subjects randomized to the intervention arm of the trial.

Inclusion criteria

• Age 30-75 years
• Transthoracic echocardiogram as of 1/1/2019
• LVH on echocardiogram
• Mass General Brigham PCP affiliation with at least 1 PCP practice visit within the last 24 months

Exclusion criteria

• Current or previous outpatient blood pressure medication prescription
• Moderate or severe aortic stenosis
• Severe concentric LVH
• Asymmetric LVH
• History of prosthetic heart valve
• Bicuspid aortic valve
• Known cardiomyopathy (or had an outpatient visit diagnosis for a cardiomyopathy)
• Autonomic dysfunction
• History of heart or lung transplantation
• Active cancer treatment plan
• Active pregnancy
• Dementia
• Individuals whose primary address is in a nursing home or long-term care facility